Demand For Latin America Pharmaceutical Products CMO Market To Gain Momentum During The Forecast Period 2027
The growing prevalence of chronic disease is driving the growth of the Latin America pharmaceutical products CMO market. For instance, according to Incidência de Câncer no Brasil, the estimated number of new cases of cancer was 600,000, excluding cases of non-melanoma skin cancer during the 2018-2019 biennium, in Brazil. Key players are focussing on the R&D of new products to expand their product portfolio which is again fostering the growth of the pharmaceutical products CMO market in the region. For instance, in December 2019, FerGene, a new gene therapy company formed as an alliance between Ferring Pharmaceuticals and Blackstone Life Sciences, announced positive results from a clinical trial that assessed the efficacy of nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer.
Minimal reimbursement offered outside the hospital settings is a prime factor hindering the growth of the Latin America pharmaceutical products CMO market.
Key players include BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific
Read More: https://bit.ly/3yAWKAr
Comments
Post a Comment